Welcome to our dedicated page for Rallybio SEC filings (Ticker: RLYB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Rallybio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Rallybio's regulatory disclosures and financial reporting.
Rallybio Corporation (NASDAQ: RLYB) has divested its 50 % ownership in RE Ventures I, LLC (the ENPP1 joint venture) to Recursion Pharmaceuticals for immediate and potential future consideration.
- Initial consideration: Recursion issued 1,457,952 Class A shares (VWAP $5.1442) valued at $7.5 million on 8 July 2025.
- Make-whole mechanism: If Rallybio’s net proceeds from selling the Initial Shares differ from $7.5 million, the party benefiting must true-up the difference in cash.
- Contingent equity: Upon achievement of specified development milestones for the ENPP1 compound, Rallybio may receive additional shares worth up to $12.5 million, with the same make-whole feature.
- Milestone & royalty stream: The agreement grants Rallybio undisclosed cash milestone payments and low-single-digit royalties on future net sales of ENPP1-related products.
- Following the sale, the ENPP1 JV becomes an indirect wholly-owned subsidiary of Recursion; Rallybio relinquishes all equity interest.
The transaction strengthens Rallybio’s liquidity with $7.5 million in equity that can be monetised, de-risks ongoing ENPP1 development costs, and leaves upside through contingent consideration and royalties. However, future value now depends on milestones achieved by Recursion, and Rallybio forgoes direct participation in the JV’s long-term upside.
Rallybio (NASDAQ:RLYB) filed an 8-K announcing a new employment agreement with Chief Medical Officer Steven Ryder, M.D.
Key terms
- Base salary: $531,227
- Annual target bonus: 40% of salary
- Initial one-year term with automatic one-year renewals
- Standard severance: 12 months salary, prior bonus and up to 12 months COBRA
- Change-in-control severance: 1.5× salary + target bonus, 18 months COBRA and full vesting of time-based equity
Severance requires a release of claims; a 12-month non-compete and non-solicitation applies. No other operational or financial updates were disclosed.